Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017

TEL AVIV, Israel, Nov. 2, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, announced today that it will host a conference call and webcast on Thursday, November 9, 2017, to discuss results for the period ended September 30, 2017 and to provide an update on current developments with respect to its clinical programs:

Conference Call & Webcast:
Thursday, November 09, 2017, 8:30 am Eastern Time / 5:30 am Pacific Time
Participant Dial-In Numbers:
Toll-Free:                     +1-877-870-4263
Toll/International:          +1-412-317-0790
Webcast:                     https://www.webcaster4.com/Webcast/Page/1726/23160

Replay, available until Nov 16, 2017
Replay Dial-In Numbers:
Toll-Free:                     +1-877-344-7529
Toll/International:          +1-412-317-0088
Passcode:                   10113655

About Therapix Biosciences:

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol):  THX-110 targets the treatment of the symptoms of Tourette Syndrome; and THX-130 targets the high-value and under-served market of mild cognitive impairments and Traumatic Brain Injury (TBI). Please visit our website for more information at www.therapixbio.com.

Forward-Looking Statements:

This press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Such forward-looking statements used in this press release include, among other things, references to the clinical and commercial potential of THX-OSA01 for the treatment of Obstructive Sleep Apnea. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding needed to continue to pursue our business and product development plans, the inherent uncertainties associated with developing new products or technologies, our ability to obtain regulatory approval for our product candidates, our ability to commercialize our product candidates, competition in the industry in which we operate and overall market conditions. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is available on the SEC's website, www.sec.gov.

For further information:

Investor Contact:
Josh Blacher, CFO, Therapix Biosciences, [email protected]
Therapix Biosciences Ltd.
For further information: +972-3-616-7055

Media Contact:
Susan Forman, DGI
+1-212-825-3210

SOURCE Therapix Biosciences Ltd

Related Links

http://www.therapixbio.com